These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

938 related items for PubMed ID: 19361839

  • 1. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM.
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM.
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [Abstract] [Full Text] [Related]

  • 4. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ, Liang LZ, Zeng ZY, Liu JH, Yuan SH, Wei M.
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
    Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM.
    Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
    [Abstract] [Full Text] [Related]

  • 6. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F, Bădulescu A, Schenker M, Popescu CF, Stoica Z.
    Rom J Morphol Embryol; 2005 Jun; 46(4):329-34. PubMed ID: 16688372
    [Abstract] [Full Text] [Related]

  • 7. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 8. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW, Wu LY, Yao HW, Hou JL, Li XG, Liu LY.
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [Abstract] [Full Text] [Related]

  • 9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG, Gershenson DM, Malpica A, Deavers M.
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [Abstract] [Full Text] [Related]

  • 10. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C.
    Cancer; 1998 Mar 15; 82(6):1096-103. PubMed ID: 9506355
    [Abstract] [Full Text] [Related]

  • 11. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
    Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC.
    Obstet Gynecol; 2006 Aug 15; 108(2):361-8. PubMed ID: 16880307
    [Abstract] [Full Text] [Related]

  • 12. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.
    Crit Rev Oncol Hematol; 2009 Sep 15; 71(3):233-41. PubMed ID: 19179095
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.
    J Clin Oncol; 2008 Dec 10; 26(35):5761-6. PubMed ID: 19001330
    [Abstract] [Full Text] [Related]

  • 14. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G, Kucukzeybek Y, Kemal-Gul M, Karaca B, Cosan-Terek M, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R.
    J BUON; 2008 Dec 10; 13(3):349-52. PubMed ID: 18979548
    [Abstract] [Full Text] [Related]

  • 15. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
    Fujii K, Takano M, Okamoto S, Sasaki N, Kita T, Kikuchi Y.
    Gan To Kagaku Ryoho; 2004 Dec 10; 31(13):2141-4. PubMed ID: 15628759
    [Abstract] [Full Text] [Related]

  • 16. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 10; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 17. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G, SOCRATES and MITO investigators.
    Oncology; 2006 Dec 10; 71(5-6):320-6. PubMed ID: 17878745
    [Abstract] [Full Text] [Related]

  • 18. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan 10; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 19. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
    Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K.
    Cancer; 2000 Jun 01; 88(11):2584-9. PubMed ID: 10861437
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D.
    J Clin Oncol; 2004 Nov 15; 22(22):4523-31. PubMed ID: 15542803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.